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ABSTRACT: The hepatic organic anion transporting poly-
peptides (OATPs) inﬂuence the pharmacokinetics of several
drug classes and are involved in many clinical drug−drug
interactions. Predicting potential interactions with OATPs is,
therefore, of value. Here, we developed in vitro and in silico
models for identiﬁcation and prediction of speciﬁc and general
inhibitors of OATP1B1, OATP1B3, and OATP2B1. The
maximal transport activity (MTA) of each OATP in human
liver was predicted from transport kinetics and protein
quantiﬁcation. We then used MTA to predict the eﬀects of a
subset of inhibitors on atorvastatin uptake in vivo. Using a data set of 225 drug-like compounds, 91 OATP inhibitors were
identiﬁed. In silico models indicated that lipophilicity and polar surface area are key molecular features of OATP inhibition. MTA
predictions identiﬁed OATP1B1 and OATP1B3 as major determinants of atorvastatin uptake in vivo. The relative contributions
to overall hepatic uptake varied with isoform speciﬁcities of the inhibitors.
■ INTRODUCTION
Drug transporting membrane proteins are major determinants
of the disposition of many registered drugs and are, therefore,
of great relevance for drug safety and eﬃcacy. This has
stimulated a considerable interest in developing a better
understanding of interactions with transporters already at the
drug discovery stage. The organic anion transporting
polypeptide 1B1 (OATP1B1/SLCO1B1) transporter is one of
the most highly expressed uptake transporters in human liver.
1
OATP1B1 has, along with OATP1B3 (SLCO1B3), been
shortlisted as a transporter of considerable importance for
drug disposition.
2 The signiﬁcance of OATP1B1 has further
been emphasized by numerous reports regarding OATP1B1
mediated clinical drug−drug interactions (DDIs)
3 as well as the
identiﬁcation of this transporter as an important pharmacoge-
nomic biomarker for simvastatin-induced adverse drug eﬀects.
4
OATP1B1, OATP1B3, and the less studied OATP2B1
(SLCO2B1) transporter are all localized in the basolateral
membrane of human hepatocytes. They mediate the uptake of
xenobiotics and endogenous compounds from the portal
bloodstream into the hepatocytes. For substrate drugs,
transport proteins, such as the OATPs, determine intracellular
concentrations and, hence, exposure to drug metabolizing
enzymes. Examples of drugs and drug classes that are substrates
of the OATPs are 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) inhibitors (statins), bosentan, and angiotensin II-
receptor antagonists.
2,3 Although there is a large substrate
overlap between the three hepatic OATPs, some compounds
have been described as speciﬁc substrates of one or another of
the OATPs, e.g., pitavastatin and prostaglandin E2 as
OATP1B1 speciﬁc substrates,
5 and paclitaxel and the gastro-
intestinal peptide hormone cholecystokinin octapeptide (CCK-
8) as OATP1B3 speciﬁc substrates.
3,6
Although, we have a relatively good understanding of OATP
substrates as well as OATP1B1 interacting drugs to date (cf.
refs 3,7), limited data is available regarding OATP1B3 and
OATP2B1 interacting drugs. So far, no global comparisons of
the known OATP interacting drugs, nor of the molecular
features of importance for inhibition of the three OATPs in the
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general inhibitors of these transporters would be of great value
in revealing transport in complex systems like hepatocytes.
A crucial factor for increasing the knowledge and
predictability of drug disposition is the establishment of in
vitro to in vivo correlations. A prerequisite for assessing and
comparing the importance of transport proteins, as well as the
impact of drug interactions in vivo, is knowledge of the maximal
transport activity (MTA) of each transport protein in the tissue
of interest; in this case, of OATPs in the human liver. Because
deep tissue measurements cannot be routinely performed in
humans for ethical reasons, ways to extrapolate in vitro activity
to in vivo conditions need to be developed. The transport
activity is dependent on the amount of functional transporter.
Therefore, information about tissue expression of transport
proteins would be beneﬁcial in the estimation of MTA, and for
the subsequent prediction of the impact of various DDIs.
The aims of this study were: (i) to identify speciﬁc and
general inhibitors of the three hepatic OATPs (OATP1B1,
OATP1B3, and OATP2B1), (ii) to study the inhibition
patterns of OATP1B1, OATP1B3, and OATP2B1 and the
molecular features that determine inhibition, and (iii) to
determine the protein expression of OATP1B1, OATP1B3, and
OATP2B1 in human liver and in in vitro cell models in order to
calculate the maximal hepatic transport activity and, thereby,
predict the importance of each OATP for uptake clearance
(CL) and DDIs in vivo.
To meet these aims, we developed in vitro screening models
for rapid identiﬁcation of OATP inhibition. We have applied
these models to investigate the inhibition potential of 225 drugs
and drug-like compounds on OATP1B1, OATP1B3, and
OATP2B1 mediated transport. Our experimental data were
used to develop multivariate computational models predicting
speciﬁc or general OATP interactions based on physicochem-
ical properties of the studied compounds. For a selected subset
of 13 compounds, concentration dependent inhibition of each
OATP was studied and compounds that could be used as
selective or general OATP inhibitors were identiﬁed. Further,
the protein expression of OATP1B1, OATP1B3, and
OATP2B1 was determined in human liver and in the in vitro
cell models. The results were used to calculate the intrinsic
hepatic uptake CL of atorvastatin for each OATP and to
determine the contribution of each transport protein to drug
interactions, using a subset of identiﬁed inhibitors.
■ RESULTS
Characteristics of the Data Set. The data set of 225
compounds used in this study was selected mainly from the
chemical space of oral drugs. An in-house data set of 142
compounds, enriched in OATP inhibitors,
7 was used as a
starting point. This data set was expanded with compounds
known to interact with other hepatic transporters and with the
major cytochrome P450 (CYP) enzymes involved in drug
elimination, giving a ﬁnal data set of 225 compounds. A
principal component analysis (PCA) of the data set resulted in
two signiﬁcant components that described 78% of the chemical
variation of the data set. The ﬁrst principal component was
mainly governed by polarity and hydrogen bonding, while the
second principal component was mainly described by lip-
ophilicity. The data set was well distributed in the oral drug
space (see Figure 1a). Outliers included large compounds such
as rifampicin and cyclosporine A.
The physicochemical descriptors of all the compounds are
summarized in Table 1 and in Supporting Information Table 1.
The molecular weight distribution ranged from 94.1 to 1214.6
g/mol, with a mean ± standard deviation of 401.6 ± 191.3 g/
mol, which is higher than the mean of orally administered drugs
(347 ± 162 g/mol
8). This is a result of the inclusion of
compounds known to interact with the OATPs, e.g., protease
inhibitors, which tend to be larger than average oral drugs.
7 The
lipophilicity, as indicated by NNLogP, varied between −2.8 and
7.2, with a mean of 2.7 ± 1.9 and the average polar surface area
(PSA) was 96.1 ± 70.2 Å2, which is in line with the range of
conventional registered oral drugs. The data set included 22%
positively charged compounds, 29% negatively charged
compounds, 43% neutral compounds, and 6% zwitterionic
compounds at pH 7.4 (see Figure 1b). Because the data set was
enriched in compounds interacting with the OATP transporters
(i.e., mainly neutral or negatively charged compounds),
7 a
higher fraction of neutral and negatively charged compounds
was found in this data set compared to the corresponding
fraction in the oral drug space.
Transport Kinetics. Human embryonic kidney 293
(HEK293) cells were stably transfected with OATP1B1,
OATP1B3, or OATP2B1. On the basis of all experiments
Figure 1. Principal components analysis (PCA) of an oral drug
reference data set
8 (gray squares; n = 529) and the data set of 225
compounds investigated for OATP inhibition (black squares; n = 225)
(a). The circle indicates the 95% conﬁdence interval of the PCA for
the oral drug reference data set. The ﬁrst principal component (x-axis)
is governed by polarity and hydrogen bonding, which increases to the
right, whereas the second principal component (y-axis) is governed by
lipophilicity, which increases upward. Distribution of molecular charge
at pH 7.4 of the 225 compounds investigated for OATP inhibition (b).
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(OATP2B1)), the mean uptake of the model substrates,
estradiol-17β-glucuronide (E17βG) or estrone-3-sulfate (E3S)
in the OATP expressing HEK293 cells, increased 13 times
(OATP1B1), 6.5 times (OATP1B3), and 44 times
(OATP2B1) compared to the passive uptake in mock-
transfected cells (for a representative experiment see Figure
2a−c). The uptake curves of model substrates and atorvastatin
(used in the in vitro−in vivo extrapolations), as well as resulting
kinetic parameters, are in line with available published data
7,9
and are presented in Figure 2d−f, Table 2, and Supporting
Information Figure 1. For all curves, both a saturable (OATP
dependent) and a linear (passive diﬀusion) component were
observed.
Interaction with the OATP Transporters. The screening
of the 225 compounds for interaction with each individual
OATP was performed at a concentration of 20 μM, as
described in the Experimental Details. A compound was
classiﬁed as an inhibitor if it signiﬁcantly decreased the uptake
of model substrate by at least 50%. In the OATP1B1
interaction study, 78 (35%) of the 225 compounds analyzed
were classiﬁed as OATP1B1 inhibitors (see Figure 3 and
Table 1). Of these, four compounds (coumestrol, diazepam,
nifedipine, and novobiocin) have not, to our knowledge,
previously been reported to interact with OATP1B1. In the
OATP1B3 and OATP2B1 interaction studies, 46 (20%) and 45
(20%) inhibitors were identiﬁed, respectively (Figure 3 and
Table 1). Of the 46 identiﬁed inhibitors of OATP1B3, 16 have
not, to our knowledge, previously been reported to interact
with OATP1B3. Of the 45 compounds identiﬁed as OATP2B1
inhibitors, 29 compounds were identiﬁed as novel inhibitors
and have not, to our knowledge, been reported to interact with
OATP2B1 in any other studies. All novel OATP inhibitors
identiﬁed in this study are summarized in Table 3.
A few compounds stimulated, rather than inhibited, the
OATP mediated transport (see Figure 3 and Table 1). Using an
equivalent deﬁnition of stimulators as of inhibitors, i.e., a
stimulator increases the transport of substrate at least 2-fold,
clotrimazole was identiﬁed as a stimulator of OATP1B3
mediated uptake of E17βG, while fendiline, progesterone, and
testosterone were found to stimulate the transport of E3S by
OATP2B1. Of these identiﬁed stimulators, fendiline is a novel
OATP2B1 stimulator, not previously reported to interact with
any OATP. Stimulation of OATP1B3 and OATP2B1 mediated
uptake by clotrimazole and progesterone has been reported
previously.
10,11 Testosterone, here identiﬁed as an OATP2B1
Table 1. continued
aInhibition of OATP1B1 mediated E17βG uptake at 20 μM. Substrate concentration used was 0.52 μM.
bInhibition of OATP1B3 mediated E17βG
uptake at 20 μM. Substrate concentration used was 1.04 μM.
cInhibition of OATP2B1 mediated E3S uptake at 20 μM. Substrate concentration used
was 1.02 μM.
dAZ oeSelma descriptors generated from SMILES (Supporting Information Table 4). Compounds were treated in their neutral states.
ePredicted charge at pH 7.4 (based on pKa values obtained using ADMET Predictor (SimulationsPlus, Lancaster, CA, USA)). + and − denotes
positively and negatively charged compounds, respectively. n denotes neutral compounds and ± denotes zwitterionic compounds.
fPredicted
solubility (using ADMET Predictor (SimulationsPlus, Lancaster, CA, USA)) in water at pH 7.4 is lower than 20 μM. However, it should be noted
that all compounds are ﬁrst dissolved in DMSO and further diluted with HBSS buﬀer giving a ﬁnal DMSO concentration ≤1% in all experiments.
gValues from Karlgren et al.
7 hCompounds or compound groups suggested as OATP1B1 substrates by Giacomini et al.
2 iCompounds or compound
groups suggested as OATP1B3 substrates by Giacomini et al.
2 jCompounds or compound groups suggested as OATP2B1 substrates by Giacomini et
al.
2 kCompounds suggested as OATP1B1 inhibitors by Giacomini et al.
2 lCompounds suggested as OATP1B3 inhibitors by Giacomini et al.
2
mCompounds suggested as OATP2B1 inhibitors by Giacomini et al.
2
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inhibitor.
11 This result is analogous with, e.g., results for the
ABC transporter multidrug resistance associated protein 2
(MRP2), where interacting compounds have been shown to
serve as both stimulators and inhibitors depending on
concentration used and other experimental factors.
12
Identiﬁcation of OATP Inhibitor Overlap Using the
Single-Point Inhibition Results. In total, 91 of the 225
investigated compounds were identiﬁed to interact with one or
more of the three OATP transporters. The number of
OATP1B1 inhibitors was almost twice as high as those of
OATP1B3 or OATP2B1 (see previous section). Twenty-seven
compounds that only inhibit OATP1B1 were identiﬁed from
the screens. This can be compared with three and nine
compounds classiﬁed as speciﬁc inhibitors of OATP1B3 and
OATP2B1, respectively (see Figure 4 and Table 1). The three
hepatic OATP transporters displayed a large inhibitor overlap,
with 26 compounds identiﬁed as common inhibitors.
OATP1B1 and OATP1B3 had the greatest similarity in
inhibition pattern, with 42 inhibitors in common. Of these,
16 did not signiﬁcantly decrease OATP2B1 mediated transport
at 20 μM used in the screening assay. In contrast, only one
compound (nefazodone) was identiﬁed as an inhibitor of both
OATP1B3 and OATP2B1 while not interacting with
OATP1B1.
Of the 225 compounds included in this study, 67 substances
are suggested as CYP substrates, inhibitors, or inducers by the
Food and Drug Administration (FDA) and/or the European
Medicines Agency (EMA).
13 Twenty-one of these 67
compounds also inhibited one or several of the OATP
transporters, indicating an interaction overlap between OATP
transporters and CYP enzymes. The largest overlap was seen
for CYP2C8 where 73% of the interacting compounds also
inhibited one or several of the OATP transporters, as illustrated
in Supporting Information Figure 2. These results are now
further investigated in our group.
Molecular Characteristics of the OATP Inhibitors. The
identiﬁed inhibitors were compared with the noninhibitors with
regard to physicochemical properties. Compounds that
stimulated substrate uptake were excluded from the analysis
of each data set. In general, the identiﬁed OATP inhibitors had
a signiﬁcantly higher lipophilicity, a larger molecular weight,
and a larger PSA compared to noninhibitors (see Table 4 and
Figure 5a−b). As expected from the annotation of OATPs as
anion transporters, a signiﬁcantly larger fraction of negatively
charged compounds was found among the inhibitors. The
importance of lipophilicity, as well as polarity and hydrogen
bonding, for OATP inhibition was also evident from the PCA
of the data set, where the inhibitors were clustered in the upper
right corner of the PCA graph (with the ﬁrst principal
component mainly described by polarity and hydrogen
bonding, and the second principal component mainly governed
by lipophilicity) as shown in Figure 5c.
Although the physicochemical properties identiﬁed as
important for inhibition of each of the three OATPs were
similar, some diﬀerences were observed. While inhibitors of
OATP1B3 had more hydrogen bond donors than non-
Figure 2. Uptake of estradiol-17β-glucuronide (E17βG) in OATP1B1
(a) and OATP1B3 (b) and of estrone-3-sulfate (E3S) in OATP2B1
expressing HEK293 cells (c) as compared to the passive uptake in
mock transfected cells in one representative experiment. Substrate
concentrations used were 0.52, 1.04, and 1.02 μM for OATP1B1,
OATP1B3, and OATP2B1, respectively. Bars represent mean ±
standard deviation (OATP1B1 and OATP2B1) or mean ± range
(OATP1B3). Michaelis−Menten kinetics of model substrate uptake in
HEK293 cells stably expressing the OATP1B1 (d), OATP1B3 (e), or
OATP2B1 (f) transporter. The intracellular accumulation of the
radiolabeled substrates was measured on a scintillation counter. Each
data point in the OATP1B1 and OATP2B1 curves represents the
mean uptake ± standard error, whereas in the OATP1B3 curve, each
replicate is shown.
Table 2. Kinetic Parameters of OATP1B1, OATP1B3, and OATP2B1 Mediated Transport
substrate Km (μM) Vmax (pmol/mg protein/min) Vmax/Km (μL/mg protein/min)
OATP1B1 estradiol-17β-glucoronide 12.20 ± 5.94 15.44 ± 3.44 1.27
OATP1B3 estradiol-17β-glucoronide 11.69 ± 3.80 10.12 ± 1.78 0.86
OATP2B1 estrone-3-sulfate 38.24 ± 10.19 455.2 ± 55.36 11.90
OATP1B1
a atorvastatin 0.77 ± 0.24 6.61 ± 1.24 8.58
OATP1B3 atorvastatin 0.73 ± 1.45 2.29 ± 1.45 3.14
OATP2B1 atorvastatin 2.84 ± 1.63 24.27 ± 8.12 8.55
aValues from Karlgren et al.
7
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bond donors was observed between the inhibitor and
noninhibitor group of OATP1B1 and OATP2B1. In addition,
OATP2B1 inhibitors seemed to be less dependent on polarity
than OATP1B1 and OATP1B3 inhibitors based on the
importance of PSA (see Table 4).
In Silico Prediction of OATP Inhibition. A computational
multivariate partial least-squares projection to latent structures
(PLS) model, discriminating inhibitors of any OATP trans-
porter from noninhibitors, was developed. This resulted in a
model based on only two molecular descriptors, NNLogP and
PSA. The model was able to predict OATP inhibitors with
accuracies of 85% and 79% for the training and test set,
respectively. The line of optimal separation between the two
classes (as depicted in Figure 6) was described by the following
equation:
+× −= NNlogP 0.0339 PSA 5.7336 0 (1)
In addition, multivariate PLS models, discriminating
inhibitors of each individual OATP from noninhibitors, were
also developed. The ﬁnal models predicted OATP1B1,
OATP1B3, and OATP2B1 inhibitors with accuracies of 73%,
81%, and 77%, respectively, for the training sets and 79%, 92%,
and 75%, respectively, for the test sets (see Figure 7a−b). The
classiﬁcation cutoﬀ values
14 for the three models, i.e.,
OATP1B1, OATP1B3, and OATP2B1, were 0.40, 0.36, and
0.32, respectively, as determined by the training sets. The
resulting regression coeﬃcients, reﬂecting lipophilicity, dipole
moment, polarity, nonpolarity, hydrogen bonding, orbital π-
energy, size, and rigidity, for the three discriminating models
are depicted in Figure 7c−e.
Speciﬁc and General OATP Inhibitors Based on IC50
Determinations. From the overlapping and speciﬁc OATP
inhibitors in Table 1, a subset of 13 compounds was chosen for
determinations of half-maximal inhibitory concentrations
(IC50) and subsequent inhibition constants (Ki). The subset
included three compounds previously suggested as general
OATP inhibitors (cyclosporine A, rifampicin, and ritonavir)
2
and three compounds commonly used as inhibitors of diﬀerent
eﬄux (ABC) transporters (Hoechst 33342, KO143, and
MK571).
8 In addition, to include potential “OATP speciﬁc”
inhibitors in a broader sense, OATP inhibitors not previously
identiﬁed as inhibitors of multidrug resistance protein 1
(MDR1), breast cancer resistance protein (BCRP), MRP2,
and/or organic cation transporter 1 (OCT1) in published
studies
8,15 were included based on the single-point inhibition
studies. Of these, ﬁve compounds were classiﬁed as speciﬁc
inhibitors of one of the OATP transporters (indometacin,
vincristine, doxorubicin, erlotinib, and pravastatin) and two
compounds were classiﬁed as general OATP inhibitors
(atazanavir and sulfasalazine). Chemical structures of the 13
compounds are provided in Figure 8.
IC50 curves, IC50, and Ki values of the 13 compounds are
summarized in Figure 9. Because low substrate concentrations
were used in all experiments (i.e., well below Km), the
calculated Ki values were close to the experimentally
determined IC50 values for all compounds. The obtained IC50
curves veriﬁed the trend seen in the single-point inhibition
assays. Using the same deﬁnition of an inhibitor as in the single-
point inhibition studies, i.e., an IC50 ≤ 20 μM, 34 of the 35 IC50
values resulted in the same classiﬁcation as in the single-point
inhibition assays. The only exception was Hoechst 33342,
which did not classify as an OATP1B1 inhibitor in the single-
point inhibition assay (48% inhibition at 20 μM) but had an
IC50 value of 19 μM.
As in our previous study on ABC transporters, we classiﬁed
an inhibitor as selective if it had a greater than 10-fold lower
IC50 value as compared to those of the other two OATP
transporters.
8 Using this deﬁnition, pravastatin (IC50 of 3.6
μM) and erlotinib (IC50 of 0.55 μM) were classiﬁed as selective
inhibitors of OATP1B1 and OATP2B1, respectively. Cyclo-
sporine A and rifampicin, both previously proposed for use as
Figure 3. Inhibition potency of all 225 compounds on OATP1B1 (a),
OATP1B3 (b), and OATP2B1 mediated transport (c) at a
concentration of 20 μM. Values are presented as mean percent
inhibition ± standard deviation. The 50% cutoﬀ value is indicated by
the dashed lines. Compounds identiﬁed as inhibitors (inhibition
≥50%) are shown in dark gray, while compounds identiﬁed as
noninhibitors or stimulators are shown in medium gray. In total, 78,
46, and 45 inhibitors of OATP1B1, OATP1B3, and OATP2B1 were
identiﬁed, respectively. For OATP1B1, inhibition values for 142 of the
225 compounds were taken from the study by Karlgren et al.
7.
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2 were identiﬁed as OATP1B1/
OATP1B3 inhibitors in the single-point inhibition assays. The
IC50 determination conﬁrmed these ﬁndings. Vincristine,
identiﬁed as a speciﬁc inhibitor of OATP1B3 in the single-
point inhibition assays, only had a 4-fold lower IC50 value for
OATP1B3 than for OATP1B1 (11 μM compared to 44 μM)
and was thus, like cyclosporine A and rifampicin, classiﬁed as an
OATP1B1/OATP1B3 inhibitor. Atazanavir, MK571, and
ritonavir were here identiﬁed as general OATP inhibitors
(IC50 values within one log unit) with IC50 values ranging
between 0.4 and 5.2 μM, 2.9 and 6.4 μM, and 1.3 and 6.1 μM,
respectively. Hoechst 33342 was also classiﬁed as a general
OATP inhibitor, although with a preference for OATP1B1/
OATP1B3 and higher IC50 values as compared to the general
inhibitors listed above. Indometacin and sulfasalazine were
classiﬁed as borderline general inhibitors but with a preference
for OATP1B1. Doxorubicin inhibited all three transporters but
at even higher concentrations (IC50 values of 41−240 μM).
Because of low solubility, complete inhibition curves could not
be generated for the BCRP speciﬁc inhibitor KO143. However,
because this compound completely inhibits BCRP at a lower
concentration (1 μM)
8 than concentrations aﬀecting the
OATPs, we conclude that it retained its BCRP speciﬁcity.
Prediction of IC50 Values from Inhibition Studies at a
Single Concentration. In parallel to experimental IC50
determinations, IC50 values for the selected subset of 13
compounds were predicted based on the percent inhibition
obtained at 20 μM in the single-point inhibition experiments
using eq 6 (see Experimental Details). These predicted IC50
values were compared to the experimentally determined values.
The predicted IC50 values agreed reasonably well with the
experimental values (see Supporting Information Figure 3).
Only two predicted values were more than 10-fold diﬀerent
from the experimental values, and, in total, 68% of the
predicted values were less than 3-fold diﬀerent from the
obtained values. This observation further supports the
Table 3. Novel OATP Inhibitors Identiﬁed
compound new inhibitor of previously known OATP interaction ref
5-carboxyﬂuorescein diacetate
(5-CFDA)
OATP1B3 OATP1B1 inhibitor 7
astemizole OATP2B1
baicalin OATP2B1
benzbromarone OATP2B1 OATP1B1 inhibitor 7,49
cholecystokinin octapeptide
(CCK-8)
OATP2B1 OATP1B1 substrate and inhibitor, OATP1B3 substrate, Oatp1b2 substrate,
Oatp1b4 substrate
5a,6a,7,50
coumestrol OATP1B1
diazepam OATP1B1, OATP2B1
diethylstilbestrol OATP2B1 OATP1B1 inhibitor 7
dipyridamole OATP1B3, OATP2B1 OATP1B1 inhibitor 7
erlotinib OATP2B1
ﬂuo-3 OATP2B1 OATP1B3 substrate 51
ﬂutamide OATP2B1
genistein OATP2B1 OATP1B1 inhibitor 52
GF120918 (elacridar) OATP2B1 OATP1B1 inhibitor 7
glycochenodeoxycholate OATP1B3,OATP2B1 OATP1B1 inhibitor, Oatp1a5 substrate 7,53
glycodeoxycholate OATP1B3,OATP2B1 OATP1B1 inhibitor, Oatp1a5 substrate 7,53
Hoechst 33342 OATP1B3
indocyanine green OATP2B1 OATP1B3 substrate, OATP1A2, OATP1B1, OATP1B3, Oatp2a1, Oatp1a1
and Oatp1c1 inhibitor
54
itraconazole OATP2B1
ivermectin OATP1B3 OATP1B1 inhibitor 7
KO143 OATP2B1
levothyroxin OATP2B1 OATP1A2, OATP1B1, OATP1C1, Oatp1a4, Oatp1a5, Oatp1c1 and Oatp4a1
substrate
55
morin OATP1B3,OATP2B1 OATP1B1 substrate and inhibitor 52
nefazodone OATP1B3, OATP2B1
nelﬁnavir OATP1B3 OATP1A2, OATP1B1 and OATP2B1 inhibitor 56
nifedipine OATP1B1
novobiocin OATP1B1, OATP1B3, OATP2B1
nystatin OATP1B3 OATP1B1 inhibitor 7
piroxicam OATP2B1
PSC833 (valspodar) OATP1B3 OATP1B1, Oatp1 and Oatp2 inhibitor 56a,57
reserpine OATP2B1 OATP1B1 inhibitor 7
silymarin OATP1B3, OATP2B1 OATP1B1 inhibitor 52,58
sulfasalazine OATP1B3, OATP2B1 OATP1B1 inhibitor 7
taurodeoxycholate OATP2B1 OATP1B3, Oatp1a1 and Oatp1a5 substrate 53b,c
taurolithocholate OATP1B3, OATP2B1 OATP1B1 substrate, OATP1B1 and skate Oatp inhibitor 7,59
tetracycline OATP2B1
tipranavir OATP1B3 OATP1B1 and OATP2B1 inhibitor 7,60
valproic acid OATP2B1
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm300212s | J. Med. Chem. 2012, 55, 4740−4763 4749applicability of simple screening protocols such as those used in
this study.
Prediction of Hepatic Intrinsic Uptake Clearance from
Maximal Transport Activity. To accurately assess the
Figure 4. Inhibitor overlap for the three investigated OATP
transporters OATP1B1 (yellow), OATP1B3 (red), and OATP2B1
(blue). In total, 91 (40%) of the 225 compounds screened inhibited at
least one of the OATP transporters studied. The number of speciﬁc
inhibitors of OATP1B1, OATP1B3, and OATP2B1 were 27, 3, and 9,
respectively. Larger inhibitor overlaps were seen between OATP1B1
and OATP1B3, and between OATP1B1 and OATP2B1, than between
OATP1B3 and OATP2B1. As many as 26 compounds were identiﬁed
as inhibitors of all three transporters at the studied concentration (20
μM).
Table 4. Diﬀerence in Physicochemical Properties between
Inhibitors (≥ 50% Inhibition) and Noninhibitors (0−50%
Inhibition) of OATP1B1, OATP1B3, and OATP2B1,
Respectively (Median Descriptor Values Are Presented)
OATP1B1
property
inhibitors
n =7 8
noninhibitors
n = 123
signiﬁcance
p
NNLogP 3.6 2.3 <0.0001
polar surface area (Å2) 121 66 <0.0001
nonpolar surface area (Å2) 454 307 <0.0001
total surface area (Å2) 564 363 <0.0001
molecular weight (g/mol) 481 325 <0.0001
negative charge (%) 53 18 <0.0001
hydrogen bond acceptors 5 3 <0.0001
hydrogen bond donors 2 2 ns
OATP1B3
property
inhibitors
n =4 6
noninhibitors
n = 141
signiﬁcance
p
NNLogP 3.8 2.7 0.0001
polar surface area (Å2) 142 70 <0.0001
nonpolar surface area (Å2) 492 307 <0.0001
total surface area (Å2) 609 369 <0.0001
molecular weight (g/mol) 514 336 <0.0001
negative charge (%) 59 23 <0.0001
hydrogen bond acceptors 7 3 <0.0001
hydrogen bond donors 3 2 0.0007
OATP2B1
property
inhibitors
n =4 5
noninhibitors
n = 133
signiﬁcance
p
NNLogP 4.0 2.3 <0.0001
polar surface area (Å2) 115 74 0.0005
nonpolar surface area (Å2) 456 316 0.0004
total surface area (Å2) 551 369 <0.0001
molecular weight (g/mol) 482 333 <0.0001
negative charge (%) 60 24 <0.0001
hydrogen bond acceptors 5 4 0.0012
hydrogen bond donors 2 2 n.s.
Figure 5. Diﬀerences in molecular properties between inhibitors and
noninhibitors of the OATPs. Distribution of polar surface area (PSA)
(a) and lipophilicity (NNLogP) (b) for the OATP inhibitors (black
bars) and the noninhibitors (gray bars). The OATP inhibitors have a
signiﬁcantly higher PSA and lipophilicity than the noninhibitors, as
assessed using the nonparametric Mann−Whitney U test. Principal
component analysis (PCA) of the 225 compounds investigated for
OATP inhibition (c). OATP inhibitors are shown as black squares and
noninhibitors as gray squares. The ﬁrst principal component (x-axis) is
governed by polarity and hydrogen bonding, which increases to the
right, whereas the second principal component (y-axis) is governed by
lipophilicity, which increases upward.
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of the MTA of each transport protein in the human liver is
required. Because transport capacity is related to the amount of
functional transport protein, we determined the membrane
protein expression in human liver samples and in our in vitro
cell models. We then related the protein expression to observed
maximal transport rates (Vmax values) in the in vitro systems
and used these data together with expression data from the
human liver to calculate the MTA in vivo (see eq 7).
Relative and Targeted Protein Quantiﬁcation of OATP
Expression in Human Liver. To obtain an appreciation of the
variability in the liver transporter expression and to select a
representative sample for targeted protein quantiﬁcation, the
relative protein expressions of OATP1B1, OATP1B3, and
OATP2B1 were ﬁrst determined in membrane fractions of
human liver from 12 individuals using a ﬁlter-aided sample
preparation (FASP) based proteomics approach.
16 On the basis
of these results, a sample, representative of the average OATP
protein expression (ﬁlled circle in Figure 10a), was selected and
used for the subsequent targeted protein quantiﬁcation. The
expression of OATP1B1, OATP1B3, and OATP2B1 was
compared with the corresponding data obtained in the in
vitro HEK293 cells overexpressing OATP1B1, OATP1B3, and
OATP2B1, respectively (Figure 10b−c). As determined by the
peptide-based targeted protein quantiﬁcations, the levels of
OATPs (liver vs overexpressing HEK293 cells) were found to
be 7.2 ± 0.3 vs 12.1 ± 0.9 (OATP1B1), 6.3 ± 0.4 vs 4.7 ± 0.4
(OATP1B3), and 4.0 ± 0.4 vs 57.3 ± 2.5 fmol/μg membrane
protein (OATP2B1), respectively.
Maximal Transport Activity Predicts Hepatic Uptake
Clearance of Atorvastatin. Atorvastatin, a substrate of all
three OATPs,
7,17 was used in in vitro to in vivo extrapolations
because its liver uptake is mainly dependent on OATP
transporters. The intrinsic uptake clearance (CLint,uptake)o f
atorvastatin for each transporter in the in vitro experiments was
extrapolated to corresponding in vivo data using the MTA. As
can be seen in Figure 10d, OATP1B1 and OATP1B3 were the
major OATP transporters responsible for the hepatic uptake of
atorvastatin in vivo, with predicted CLint,uptake of 450 and 370
μL/min/g liver, respectively. This corresponds to a contribu-
tion to the overall uptake CL of atorvastatin of 52% and 42%,
respectively, while the remaining 6% is cleared by OATP2B1.
Impact of the Maximal Transport Activity on Drug−Drug
Interactions. Using a static mathematical model and assuming
competitive inhibition, the impact of 10 μM of the 13 selected
inhibitors on hepatic atorvastatin uptake CL in vivo was
estimated.
18 The results indicated that pravastatin, identiﬁed as
as p e c i ﬁc inhibitor of OATP1B1 in this study, almost
exclusively inhibited the uptake of atorvastatin by OATP1B1
(75% reduction) with only a minor impact on the uptake by
OATP1B3 and OATP2B1 (15% and 5% reduction, respec-
tively) (see Figure 10d−e). As a result of the pronounced
OATP1B1 inhibition, the uptake CL became more dependent
on OATP1B3 and OATP2B1 compared to the situation
without an inhibitor. In total, the overall CLint,uptake was reduced
by 45% in the presence of pravastatin.
Erlotinib, on the other hand, identiﬁed by us as a speciﬁc
inhibitor of OATP2B1, primarily decreased the contribution of
OATP2B1 to atorvastatin uptake (CLint,uptake reduced from 53
to 2.7 μL/min/g liver, a reduction of the remaining transporter
activity by 95%). However, due to the low contribution of
OATP2B1, the total reduction of the overall CLint,uptake in the
presence of erlotinib was only 32% (see Figure 10e). In fact,
inhibition of OATP1B1 by erlotinib had a larger impact on
overall atorvastatin uptake CL in quantitative terms (CLint,uptake
by OATP1B1 reduced from 450 to 290 μL/min/g liver, i.e., a
36% reduction) than the inhibition of OATP2B1. This can be
explained by a combination of a higher MTA for OATP1B1
and a lower aﬃnity of atorvastatin for OATP2B1.
Atazanavir, identiﬁed as a general inhibitor in this study,
inhibited the uptake of atorvastatin by all three OATPs. Overall,
uptake CL was decreased by 91% and the remaining uptake CL
was mainly dependent on OATP1B1 (Figure 10d). Finally,
sulfasalazine, a borderline general inhibitor with a preference
for OATP1B1 over OATP1B3, had a large impact on
OATP1B1 mediated uptake (95% reduction). This resulted
in a clear shift in the contribution of each transporter to the
overall uptake of atorvastatin, increasing the OATP1B3
contribution from 42% to 85%. Thus, in this case, OATP1B3
became the major transporter contributing to atorvastatin
uptake (Figure 10e).
In general, for all these DDIs, the contribution of OATP2B1
to the uptake CL of atorvastatin was minor. This is a result of
the lower MTA of OATP2B1 in combination with the lower
aﬃnity for atorvastatin as compared to OATP1B1 and
OATP1B3. With some inhibitors though, the OATP2B1
contribution increased up to 6-fold (e.g., cyclosporine A and
rifampicin being OATP1B1/OATP1B3 speciﬁc inhibitors) (see
Figure 10e). However, it should be noted that even in cases
where the OATP2B1 contribution increases as compared to the
other two OATPs, the maximal OATP2B1 CLint,uptake of
atorvastatin cannot exceed 53 μL/min/g liver. This clearly
highlights the importance of OATP1B1 and OATP1B3 as
atorvastatin uptake transporters. Nevertheless, the importance
of OATP2B1 interactions will increase for substrates with
higher aﬃnity for OATP2B1 than for the other OATPs.
■ DISCUSSION
Liver expressed OATPs are considered some of the most
important drug transporting proteins in humans and the
pharmaceutical industry is recommended to examine new drug
candidates for probable interactions with these proteins.
2 This
has created a need for in vitro screening of OATP mediated
Figure 6. Discrimination between inhibitors and noninhibitors of the
OATPs using two variables only: NNLogP and PSA. The
corresponding model separated the two classes (here visualized with
a black line) with an accuracy of 85% for the training set and 79% for
the test set.
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2,19 A problem when investigating such
interactions is that many of the proposed inhibitors of OATP
transporters have not been studied for their speciﬁcity toward
the three hepatic OATPs. We therefore set out to investigate
the inhibitor speciﬁcity for a data set of 225 structurally diverse
oral drugs and drug-like compounds enriched with known and
putative OATP inhibitors. We also introduced the maximal
transport activity which allows determination of the maximal
transport capacity of each transport protein in the human liver
in vivo.
While several studies on OATP1B1 mediated drug
interactions have been performed previously (cf. ref 3,7), less
is known about global drug interaction patterns with OATP1B3
and, in particular, OATP2B1. Here, we observed a large overlap
between the inhibitors of the three OATPs and especially
between OATP1B1 and OATP1B3, which is in agreement with
the high (80%) amino acid sequence homology between these
two transporters.
No crystal structures of the OATPs are available, but
attempts to develop pharmacophore models from smaller data
sets suggest that hydrogen bond features and lipophilicity are
important properties of OATP1B1 substrates.
20 This agrees
well with an interesting aspect of the OATP inhibitors in this
study; they beneﬁt from being both lipophilic and being polar.
While NNLogP has been positively correlated to inhibition of
both eﬄux and uptake transporters, PSA has either not been
identiﬁed as an important molecular property or has been
negatively correlated to inhibition of other hepatic transporters
in previous studies.
8,15,21 As shown here for the investigated
compounds, a larger PSA generally results in a lower NNLogP.
Hence, a number of diﬀerent structures may exhibit inhibitory
characteristics. A large structural diversity has also been
observed for inhibitors of E17βG uptake in human hepatocytes,
which, presumably, is mainly the result of inhibition of
OATP1B1/OATP1B3.
22
The result that inhibitors beneﬁt from increase in both
lipophilicity and polar surface area supports the speculation that
there are several interaction sites for these transporters and that
a variety of diﬀerent structures may act as inhibitors of
OATP1B1, OATP1B3, and OATP2B1. Although most
Figure 7. Accuracy of the prediction of OATP1B1, OATP1B3, and OATP2B1 inhibitors and noninhibitors in the training set (a) and in the test set
(b) for the developed individual PLS models. The bars represent the percentage of correctly classiﬁed inhibitors (black) and noninhibitors (gray).
Comparison of the PLS regression coeﬃcients for the molecular descriptors included in the ﬁnal discriminating models and their correlation to
inhibitors, or noninhibitors, for the OATP1B1 (c), OATP1B3 (d), and OATP2B1 model (e). Descriptors with large absolute coeﬃcients have a
large inﬂuence on the discriminant model. The included descriptors are Hückel molecular orbital π-energy (HMO pi-energy), total hydrogen bond
acceptor strength (HYBOT_sum_acceptor), total hydrogen bond (hydrogen bond acceptors and donors) strength (HYBOT_sum_total), number
of hydrogen bond acceptors (HB-acceptors), polar surface area (PSA), total surface area (TSA), nonpolar surface area (NPSA), dipole moment
based on Gasteiger atomic charges (Dipole moment Gast.), number of rigid fragments in the molecule (Num. rig. frag.), two-dimensional dipole
moment (Dip. mom. 2D (G+H)) and lipophilicity (NNLogP).
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binding sites could explain the few exceptions with slopes much
less than unity (see Figure 9 and Supporting Information Table
2). Results supporting the existence of two binding sites have
previously been provided for OATP1B1
23 and for OATP2B1
24
based on biphasic uptake kinetics of E3S. In addition, allosteric
interaction sites aﬀecting the uptake of pravastatin by
OATP1B1 and OATP1B3 were discussed in a recent
publication.
25
The number of inhibitors of each transporter was suﬃciently
large to investigate molecular descriptors of importance for
inhibition of the individual OATP transporters and to develop
in silico models that are able to predict inhibition with good
accuracy. Our modeling reveals the somewhat diﬀerent
behavior of OATP2B1 relative to OATP1B1 and OATP1B3
(Figure 7c−e). The OATP2B1 model, contrary to those of the
other two transporters, has a negative contribution of nonpolar
(NPSA) and total surface area (TSA). However, as shown in
Table 4, the OATP2B1 inhibitors have a signiﬁcantly higher
NPSA and TSA than the noninhibitors. This may be explained
by the presence of a subgroup of OATP2B1 noninhibitors with
large NPSA and TSA (e.g., cyclosporine A, ivermectin, and
PSC833). The linear model thus includes a negative
contribution of these descriptors, enabling correct predictions
of OATP2B1 inhibition potency also for such compounds.
Among the compounds classiﬁed as speciﬁc OATP1B1
inhibitors, we ﬁnd the three statins, lovastatin acid, pravastatin
acid, and simvastatin acid. This is in line with the impact of
OATP1B1 polymorphisms on the pharmacokinetics
26 and
dynamics
4 of statins. For OATP1B3, only three speciﬁc
inhibitors could be identiﬁed (the novel inhibitor Hoechst
33342, as well as the previously known interacting drugs
mitoxantrone and vincristine
27). Erlotinib, a tyrosine kinase
inhibitor used in the treatment of several forms of cancer,
28 was
the only strong selective OATP2B1 inhibitor identiﬁed.
Comparison with the maximum unbound plasma concentration
Figure 8. Molecular structures of the 13 inhibitors selected for experimental determination of IC50 values. Compounds identiﬁed as selective
inhibitors of a single OATP transporter are shown in the top section. Partially overlapping inhibitors (i.e., inhibiting two of the three OATP
transporters) are shown in the middle section, and below, in the bottom section, general inhibitors of the OATPs are displayed. The inhibitors are
grouped according to transporter preference based on the IC50 experiments (see Results). For KO143, complete inhibition curves could not be
generated and, hence, its placement was based on the highest concentration used.
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm300212s | J. Med. Chem. 2012, 55, 4740−4763 4753Figure 9. Concentration dependent inhibitory eﬀect of atazanavir (a), cyclosporine A (b), doxorubicin (c), erlotinib (d), Hoechst 33342 (e),
indometacin (f), KO143(g), MK571 (h), pravastatin (i), rifampicin (j), ritonavir (k), sulfasalazine (l), and vincristine (m) on OATP1B1 (black
triangles, dashed black line), OATP1B3 (red circles, dotted red line), and OATP2B1 (open squares, solid blue line) mediated transport. IC50 and Ki
values were determined using Prism v.4.02 (GraphPad Software, La Jolla, CA, USA) and eqs 4−5. Tabulated IC50 and Ki values of the 13 selected
compounds (n). Erlotinib and pravastatin show selective inhibition of OATP2B1 and OATP1B1, respectively. Cyclosporine A and rifampicin can be
considered as OATP1B1/OATP1B3 inhibitors with IC50 values of 1.2−1.5 μM for both OATP1B1 and OATP1B3 but more than one log unit
higher IC50 values (about 30−40 times higher) for OATP2B1. A similar pattern is seen for vincristine, although this compound is a weaker
OATP1B1/OATP1B3 inhibitor. Indometacin and sulfasalazine were borderline general inhibitors but with a preference for OATP1B1. Atazanavir,
doxorubicin, Hoechst 33342, MK571, and ritonavir had comparable aﬃnity for the three OATP transporters with IC50 values being within one log
unit.
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dx.doi.org/10.1021/jm300212s | J. Med. Chem. 2012, 55, 4740−4763 4754Figure 10. Prediction of in vivo intrinsic uptake clearance (CLint,uptake) based on protein expression data. Relative membrane protein expression of
OATP1B1, OATP1B3, and OATP2B1 in 12 human liver samples (a). One sample (ﬁlled black circle), with relative expression levels close to the
average expression of all 12 liver tissues, was used for targeted protein quantiﬁcation to obtain the membrane protein expression of OATP1B1,
OATP1B3, and OATP2B1. The surrogate peptide levels in the selected liver sample (black bars) and in membrane fractions of stably transfected
HEK293 cells (white bars) are shown in fmol/μg membrane protein (mean ± standard deviation for three measurements (or mean ± range for two
measurements, OATP1B1 in vitro, indicated with *). (b−c). Predicted CLint,uptake of atorvastatin by OATP1B1 (yellow), OATP1B3 (red), and
OATP2B1 (blue) without inhibitor or with 10 μM pravastatin, erlotinib or atazanavir (d). Tabulated values of predicted CLint,uptake, contribution of
each OATP to the overall uptake CL as well as remaining individual or overall OATP dependent CLint,uptake of atorvastatin in the absence of an
inhibitor or in the presence of 10 μM of each of the 13 selected inhibitors (e).
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29) reveals that erlotinib probably inhibits
OATP2B1 at clinically relevant concentrations.
Erlotinib also inhibits several other transporters, including
the abundantly expressed organic cation transporters OCT1
1a
and multidrug and toxin extrusion 2K (MATE2K)
29 as well as
the ABC transporters BCRP, MDR1,
30 and MRP7.
31 This
complexity is shared by many other inhibitors in this study.
Pravastatin, here identiﬁed as an OATP1B1 speciﬁc inhibitor,
has been reported to be a substrate of MDR1, BCRP, and
MRP2.
32 Sulfasalazine, here classiﬁed as a borderline general
OATP inhibitor, is also a substrate of BCRP.
33 Finally, MK571,
identiﬁed as a general ABC inhibitor by Matsson and co-
workers,
8 was also identiﬁed as an OATP inhibitor in this study
with IC50 values ranging between 2.9 and 6.4 μM as compared
to 26 μM (MDR1), 50 μM (BCRP), and 10 μM (MRP2) for
the ABC transporters.
8 This analysis emphasizes the signiﬁcant
impact of interactions with various drug transporting proteins
on the pharmacokinetics of drugs. We conclude that to be
interpretable, screening studies of transporter interactions in
drug discovery should be performed under conditions that
allow for the investigation of each transport protein in isolation.
For this purpose, the new speciﬁc and general inhibitors of the
three OATPs found in this study will be useful tools.
On the basis of this study, we suggest pravastatin and
erlotinib as speciﬁc in vitro inhibitors of OATP1B1 and
OATP2B1, respectively. In addition, we conclude that cyclo-
sporine A and rifampicin can be used as OATP1B1/OATP1B3
inhibitors, with little eﬀect on OATP2B1. We also conﬁrm the
recommendation of ritonavir as a general OATP inhibitor
2 and
suggest atazanavir as another general OATP inhibitor. Finally,
when considering a general inhibitor of both the hepatic
OATPs and ABC transporters, MK571 is the compound with
the highest potential, taking into account the results from this
as well as from previous studies.
8
Given the complexity of drug interaction patterns with
transport proteins, it may seem impossible to predict the in vivo
impact of such interactions. Here, we present a new approach
to handle this issue for individual transporters. By introducing
the concept of MTA, the transport capacity in vitro (Vmax) can
be linked to the transport activity in the human liver in vivo.
The major underlying assumption is that all transport proteins
in the isolated membrane fractions are available for drug
transport both in vitro and in vivo (see Experimental Details for
additional assumptions with respect to eq 7). When this is the
case, the maximal transport capacity is directly linked to the
Vmax value in the in vitro model and a scaling factor giving an
assumed Vmax value in vivo can be obtained according to eq 7.
We underscore that the MTA represents an ideal situation,
where it is assumed that all transport protein is active. For
instance, intracellular pools of transport proteins are not
accounted for. It has been stated, however, that OATPs are not
stored in intracellular compartments.
34
As in previously published work, based on the so-called
relative expression factor,
5a the highest relative protein
expression was observed for OATP1B1. The large variability
in OATP1B1 expression between donors (Figure 10a) could be
a result of variable expression due to common genetic variants
of this protein.
19,35 This is in line with previous studies, where
similar interindividual variations in human liver OATP
expression have been reported.
1b,36 In addition, the protein
expression levels obtained using targeted protein quantiﬁcation
were in reasonably good agreement with these reports.
1b,36
Because we identiﬁed atorvastatin as a substrate of all three
OATPs in this study, we could compare the uptake clearance
values of the three OATP transporters in vitro. As can be seen
in Table 2, OATP2B1 transported atorvastatin with the highest
eﬃciency (Vmax/Km) in vitro. This is presumably due to a high
OATP2B1 expression in the in vitro cell model. When taking
the MTA into account to calculate intrinsic uptake clearance in
the human liver, the contribution of OATP2B1 mediated
transport to the overall uptake clearance of atorvastatin was
however reduced to a minimum.
The impact of a series of inhibitors with diﬀerent inhibition
patterns (IC50 values) on each of the OATPs was markedly
altered when the MTA was considered. One such example is
erlotinib, where the inhibition of OATP1B1 and OATP1B3 was
more signiﬁcant than the OATP2B1 inhibition in quantitative
terms even though erlotinib was identiﬁed as an OATP2B1
speciﬁc inhibitor (Figure 10d). Importantly, this ﬁnding does
not preclude the application of erlotinib as a highly speciﬁc
OATP2B1 inhibitor under controlled in vitro conditions. Note
that for the predictions in Figure 10d−e, a ﬁxed concentration
of 10 μM was used for all inhibitors. However, if evaluating the
risk of clinical DDIs, unbound plasma concentrations in vivo
are the most accurate input variables to use (cf. ref 2).
Interestingly, the substantial contribution of OATP1B3 to
atorvastatin uptake clearance as well as the overlapping
speciﬁcities of many inhibitors suggest that OATP1B3 is
more important for known clinical DDIs than previously
understood. For example, both cyclosporine and rifampicin
have been reported to aﬀect atorvastatin pharmacokinetics in
clinical studies.
19 Cyclosporine is an inhibitor of several drug
transporters and metabolizing enzymes.
2,37 In vivo, concom-
itant administration of atorvastatin and cyclosporine has
resulted in vastly increased plasma concentrations of
atorvastatin (7.4−15.3-fold increase (cf. ref 19)). This eﬀect
has mainly been attributed to inhibition of OATP1B1 mediated
uptake and inhibition of CYP dependent metabolism (cf. ref
38). Our results, taking MTA into consideration, reveal that
inhibition of OATP1B3 mediated uptake of atorvastatin might
be almost equally important as OATP1B1 inhibition. Indeed,
for both OATP1B1 and OATP1B3, only 11−12% of the
predicted activity is remaining when the dual OATP1B1/
OATP1B3 inhibitor cyclosporine is used (Figure 10e).
With rifampicin, a similar situation prevails. Concomitant
single-dose treatment with atorvastatin and rifampicin has
resulted in 6.8-fold increased plasma concentration in vivo,
which has been attributed to OATP1B1.
39 Also here, our
results indicate that rifampicin greatly reduces both OATP1B1
and OATP1B3 mediated atorvastatin uptake (Figure 10e).
Hence, the role of OATP1B3 needs to be reconsidered. In light
of the large inhibitor overlap between OATP1B1 and
OATP1B3 displayed in Figure 4, it is likely that similar
conditions will apply for other drugs administered in
combination with a shared OATP1B1/OATP1B3 substrate.
Clarithromycin (73.1% inhibition of OATP1B1, 53.8%
inhibition of OATP1B3), which has been reported to increase
atorvastatin AUC 4.5-fold, could be one such example.
40
■ CONCLUSION
In summary, our results speak in favor of considering
transporter expression levels in DDI studies. As exempliﬁed
above, many of the compounds identiﬁed as OATP inhibitors
also interact with other drug transporters in vitro. The
importance of individual interactions for the overall in vivo
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without knowledge of diﬀerences in protein expression levels
between systems. As more quantitative information on
transporter protein levels become available, more accurate
scaling from in vitro to in vivo can be performed, which will
further improve predictions of drug disposition and DDIs.
Importantly, the MTA introduced here does not only apply to
the liver. It can also be applied in predictions of transporter
impact in other cells and tissues.
■ EXPERIMENTAL DETAILS
Chemicals. The 225 compounds investigated in the inhibition
assays were obtained from Sigma-Aldrich Corp. (St. Louis, MO, USA),
Toronto Research Chemicals Inc. (North York, ON, Canada),
International Laboratory USA (San Bruno, CA, USA), 3B Scientiﬁc
Corp. (Libertyville, IL, USA), and AstraZeneca (Mölndal, Sweden).
Bufuralol was kindly provided by Dr. Inger Johansson, Karolinska
Insititutet, Stockholm, Sweden. Aciclovir, amantadine, buspirone,
daidzein, doxazosin, etoposide, fenoﬁbrate, ﬂuoxetine, ﬂuvoxamine,
furafylline, lamotrigine, mitoxantrone, nifedipine, oﬂoxacin, phenyl-
butazone, procainamide, propranolol, ranolazine, sanguinarine, sulfa-
phenazole, tetraethylammonium, tolbutamide, tranylcypromine, val-
proic acid, and verapamil were obtained as DMSO stocks from
LOPAC (Sigma-Aldrich Corp., St. Louis, MO, USA). Radioactively
labeled E17βG( 3H-E17βG) and E3S (3H-E3S) were purchased from
PerkinElmer (Waltham, MA, USA).
Compound Selection. A data set of structurally diverse
compounds previously used in a study of OATP1B1 inhibition was
used as a starting point for the compound selection.
7 This data set
contained compounds reﬂecting the oral drug space as well as
compounds identiﬁed in the literature as interacting with OATPs. The
data set was further expanded with compounds highlighted in the
recently published review on drug transporters by the international
transporter consortium.
2 Compounds generally used as substrates,
inhibitors, or inducers in CYP studies were also included in the ﬁnal
data set.
13
Establishment of Stable Cell Lines and Cell Cultivation. Total
human liver RNA was obtained from Clontech (Mountain View, CA,
USA). Reverse transcription was performed using the SuperScript III
ﬁrst-strand synthesis supermix according to the manufacturer’s
instructions (Invitrogen, Carlsbad, CA, USA). The resulting cDNA
was used as a template when SLCO1B3/OATP1B3 and SLCO2B1/
OATP2B1 were ampliﬁed using Platinum Pfx DNA polymerase
(Invitrogen, Carlsbad, CA, USA) and gene speciﬁc primers (see
Supporting Information Table 3). The PCR products were cloned into
the BamHI/XhoI (OATP1B3) or the HindIII/EcoRV (OATP2B1)
sites of the expression vector pcDNA5/FRT (Invitrogen, Carlsbad,
CA, USA). The sequences of the obtained OATP1B3-pcDNA5/FRT
and OATP2B1-pcDNA5/FRT constructs were veriﬁed by DNA
sequencing and were found to be identical with the SLCO1B3*2 (the
most common SLCO1B3 allele having an allele frequency of up to 88%
in Caucasians
41)a n dSLCO2B1*1 (NCBI SLCO2B1 reference
sequence: NM_007256) alleles, respectively. HEK293 Flp-In cells
(Invitrogen, Carlsbad, CA, USA) were transfected with the
constructed OATP1B3- and OATP2B1-pcDNA5/FRT expression
vectors and further selected using hygromycin B (Invitrogen, Carlsbad,
CA, USA) as previously described for OATP1B1 and mock transfected
cells.
7 HEK293 cells were used because the endogenous background
expression of transport proteins and drug metabolizing enzymes is
either very low or absent.
42 For continued maintenance, all stable
clones were cultured as described by Karlgren et al.
7
Transport Experiments. Two days prior to transport experiments
with E17βG or E3S,
43 OATP1B1,
7 and OATP2B1 overexpressing cells
were seeded in 96-well CellBind plates (Corning, Amsterdam,
Netherlands) at a density of 100000 cells per well. For all experiments
with OATP1B3 expressing cells or with atorvastatin as substrate, cells
were seeded in 24-well CellBind plates (Corning, Amsterdam,
Netherlands) three days prior to transport experiments at a density
of 600000 cells per well. Cell density was optimized by computer
assisted experimental design using MODDE 7.0 (Umetrics, Umeå,
Sweden) as described elsewhere.
7 For culturing in 96- and 24-well
plates, Flp-In-293 medium without phenol red and hygromycin B was
used.
7
Characterization of OATP1B1, OATP1B3, and OATP2B1 Medi-
ated Transport. To determine the binding aﬃnity (Km) and maximal
transport rate (Vmax) of the OATP1B1 and OATP1B3 mediated
uptake of model substrate (E17βG), OATP1B1-HEK293 cells grown
in 96-well plates were incubated with a solution containing 1 μCi/mL
(20.4 nM) of 3H-E17βG and 0.5−100 μM of unlabeled E17βGi n
HBSS, and OATP1B3-HEK293 cells grown in 24-well plates were
incubated with a solution containing 2 μCi/mL (40.9 nM) of 3H-
E17βG and 1−100 μM of unlabeled E17βG in HBSS. The Km and
Vmax of the OATP2B1 model substrate, E3S, were determined using
OATP2B1-HEK293 cells grown in 96-well plates. The cells were
incubated with a solution containing 1 μCi/mL (21.9 nM) of 3H-E3S
and 0.5−600 μM of unlabeled E3S in HBSS. The uptake of model
substrate was analyzed using a scintillation counter as described below.
To characterize the OATP1B3 and OATP2B1 mediated atorvastatin
uptake, cells grown in 24-well plates were incubated with a solution
containing 0.01−20 μM atorvastatin in HBSS and intracellular
accumulation was analyzed using LC-MS/MS as previously described.
7
Uptake kinetics of E17βG, E3S, and atorvastatin were assessed by
plotting the initial uptake rate (uptake after 1 min) against substrate
concentration [S], and the apparent Km and Vmax were determined
using nonlinear regression (Prism v.4.02 from GraphPad Software, La
Jolla, CA, USA) ﬁtted to eq 2.
=
×
+
+× V
V
K
P
[S]
[S]
[S]
max
m
diff
(2)
where Pdiﬀ is the passive permeability of the substrate.
Substrate concentrations well below the Km were selected for
subsequent inhibition studies with the radiolabeled model compounds.
Linearity of E17βG and E3S uptake over time, in the three OATP
expressing HEK293 cell lines, was assessed using the selected substrate
concentrations for up to 10 min incubation time. The OATP1B1 and
OATP1B3 mediated uptake of E17βG was linear over the ﬁrst 10 min,
and the OATP2B1 mediated uptake of E3S was linear for the ﬁrst 5
min. All uptake experiments were performed in the linear interval.
Single-Point Inhibition Studies. The screening for inhibition of
OATP1B1 mediated uptake of E17βG was performed at an inhibitor
concentration of 20 μM, as previously described.
7 In total, 225
compounds were investigated. Inhibition values for 142 of these
compounds were taken from a previous screen of OATP1B1
inhibition.
7
For the OATP1B3 and OATP2B1 single-point inhibition assays,
experimental design was used to optimize the assays with regard to
substrate concentration, amount of labeled substrate, incubation time,
number of washes, cell seeding density, and days in culture before the
experiments. The MODDE 7.0 (Umetrics, Umeå, Sweden) software
was used for setup and evaluation of the experimental design as
described previously.
7 In the OATP1B3 inhibition assay, cells grown in
24-well plates were incubated for 5 min with a solution containing 20
μM of the test compound, 2 μCi/mL (40.9 nM) of 3H-E17βG, and 1
μM of unlabeled E17βG in HBSS. In the OATP2B1 inhibition assay,
cells grown in 96-well plates were incubated for 4 min with a solution
containing 20 μM of the test compound, 1 μCi/mL (21.9 nM) of 3H-
E3S, and 1 μM of unlabeled E3S in HBSS. All 225 compounds in the
data set were screened for OATP1B3 and OATP2B1 inhibition.
On each plate, HEK293 cells were incubated with substrate solution
as a positive control of OATP mediated uptake (OATP expressing
cells) and the passive permeability was obtained from mock
transfected cells. In addition, pitavastatin, taurocholate, or atorvastatin
was included on each plate as a positive control of inhibition. Percent
inhibition was calculated according to eq 3.
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm300212s | J. Med. Chem. 2012, 55, 4740−4763 4757=−
−
−
×
+
−
⎛
⎝
⎜ ⎜
⎞
⎠
⎟ ⎟ inhibition (%) 1
uptake uptake
uptake uptake
100
OATP inhibitor mock
OATP inhibitor mock
(3)
A compound was classiﬁed as an inhibitor if it decreased the uptake
of model substrate by at least 50% (2-fold decrease).
7,8,15,21 Likewise, a
compound was classiﬁed as a stimulator if it increased the uptake by at
least 100% (2-fold increase).
IC50 Determinations. The half-maximal inhibitory concentration,
IC50, for a subset of 13 compounds was determined in vitro, using the
same methodology as in the single-point inhibition studies. To include
potential “OATP speciﬁc” inhibitors in a broader sense, OATP
inhibitors not identiﬁed as inhibitors of the ABC-transporters MDR1,
BCRP, MRP2, and/or the organic cation transporter OCT1 in
previously published studies
8,15 were selected from the data set. With
this prerequisite, ﬁve of the 13 compounds, identiﬁed as either speciﬁc
(doxorubicin, erlotinib, indometacin, and vincristine) or general
(sulfasalazine) OATP inhibitors in the single-point inhibition assays,
were selected. Additionally, three compounds recommended as OATP
inhibitors (rifampicin, ritonavir, and cyclosporine A),
2 three commonly
used ABC inhibitors (Hoechst 33342, KO143, and MK571),
8 and two
compounds belonging to drug classes with clinically relevant OATP
mediated drug−drug interactions (atazanavir and pravastatin) were
investigated. In the IC50 experiments, 5−12 inhibitor concentrations
were used in the following concentration intervals: atazanavir 0.02−
40 μM, cyclosporine A 0.01−25 μM, doxorubicin 0.1−1000 μM,
erlotinib 0.02−400 μM, Hoechst 33342 0.1−600 μM, indometacin
0.1−600 μM, KO143 0.05−10 μM, MK571 0.01−100 μM, pravastatin
0.1−400 μM, rifampicin 0.05−400 μM, ritonavir 0.01−50 μM,
sulfasalazine 0.01−100 μM, and vincristine 0.1−600 μM. IC50 values
were calculated by ﬁtting the data to the following equation using
Prism v.4.02 (GraphPad Software, La Jolla, CA, USA).
=
+
−× substrate uptake (% of control)
100
11 0
(Log[I] LogIC ) Hill Slope 50
(4)
This is equal to the four-parameter equation when the bottom
plateau of the curve is constrained to zero and the top plateau to 100.
[I] is the inhibitor concentration, and the Hill Slope describes the
steepness of the curve.
The inhibition constant, Ki, was calculated according to eq 5
(assuming competitive inhibition).
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In parallel to the experimental determinations, predicted IC50 values
for the 13 compounds were calculated based on the obtained single-
point inhibition results using eq 6.
=× − ⎜⎟ ⎛
⎝
⎞
⎠ IC [I]
100
%inhibition
1 50 (6)
Compounds showing negative inhibition values (i.e., stimulation of
the uptake) in the single-point inhibition studies, and compounds
where no experimental IC50 value could be determined, were excluded
from the IC50 predictions.
Scintillation Analysis. At the end of the incubation with
radioactively labeled substrate solutions, carrier-mediated uptake was
stopped by addition of ice-cold PBS followed by three or four washes.
The cells were lysed using 1 M NaOH. Analysis of intracellular
accumulation of radioactively labeled model substrate was carried out
on a TopCount NXT scintillation counter using Luma plates
(OATP1B1 and OATP1B3) or Opti plates with addition of 250 μL
of Microscint 20 scintillation liquid (OATP2B1), respectively. All
plates, scintillation liquids, and equipment were obtained from
PerkinElmer, Inc. (Downers Grove, IL, USA).
Protein Concentration Measurements. In all uptake kinetics or
inhibition experiments, cell lysates (obtained by addition of 1 M
NaOH as described above) were neutralized using 1 M HCl. Total
protein content was measured using the BCA Protein Assay Reagent
Kit (Pierce Biotechnology, Rockford, IL, USA) according to
manufacturer’s instructions.
Statistics. All experiments were performed in duplicate
(OATP1B3) or triplicate (OATP1B1 and OATP2B1) on 2−6
independent occations. In each experiment, ANOVA and Dunnett’s
multiple comparison test were used to ensure that the uptake in
presence of inhibitor/stimulator was signiﬁcantly diﬀerent from the
positive OATP control where no inhibitor/stimulator was used.
Molecular Descriptors. The 225 compounds used in this study,
together with an oral drug reference data set,
8 were treated in their
neutral states and characterized using the AZ oeSelma descriptors
generated from SMILES (see Supporting Information Table 4 for a
compilation of the structures in SMILES format). The AZ oeSelma
descriptors consist of AstraZeneca’s in-house compilation of 93
molecular descriptors, of physicochemical nature, in line with the work
of Labute.
44 These descriptors contain 1D and 2D descriptors,
including properties such as various counts of atoms and bonds,
charges, surfaces, and lipophilicity. In addition, charge and solubility in
water at pH 7.4 were predicted using ADMET Predictor
(SimulationsPlus, Lancaster, CA, USA). Signiﬁcant diﬀerences
between the groups of inhibitors and noninhibitors, with regard to
physicochemical properties, were assessed using the nonparametric
Mann−Whitney U test.
Computational Modeling. The overall characteristics of the data
set were assessed using PCA implemented in Simca-P (version 12.0 of
the Simca-P software, Umetrics AB, Umeå, Sweden). The data set was
also assessed on a PCA model where the 529 oral drugs in the
reference data set were used as a training set and the OATP data set
was projected onto that model. Modeling of the inhibition of the three
transporters (OATP1B1, OATP1B3, and OATP2B1) was performed
using the PLS method implemented in Simca-P (version 12.0 of the
Simca-P software, Umetrics AB, Umeå, Sweden). Each model was
developed as a classiﬁcation model where the cutoﬀ for inhibition was
set to 50%. Compounds exhibiting inhibition greater than 50% were
designated as inhibitors (class = 1), and compounds exhibiting
inhibition less than 50% were considered to be noninhibitors
(class = 0).
For all three models, compounds exhibiting inhibition <0%, i.e.,
stimulation of the transport, were excluded from the modeling. The
data sets were split into a training set and a test set, where a third of
the data set was randomly selected as the test set. Because of skewed
distributions of inhibitors and noninhibitors of the three transporters
(the former class being between 33% and 38% in the respective
training sets), the cutoﬀ value, normally set to 0.5 for equally
distributed classes, was adjusted during model development using the
training sets to optimize accuracy. The data were mean-centered and
scaled to unit variance. A variable selection procedure was applied on
the training sets, where variables exhibiting low variable importance
were removed stepwise. The aim of the variable selection was to
maintain predictability and increase the robustness of the models. At
the same time, the complexity of the models was decreased, facilitating
interpretation by removing information that was not directly related to
the response variable (i.e., noise). The variable selection was validated
by the 7-fold cross-validated R2 (Q2) for the training sets. The selected
variables for the three transporters were subsequently used to derive
the ﬁnal models and the qualities of these models were judged by the
accuracies of the respective test sets.
A general OATP inhibition model was also developed as described
above, whereby a compound was deﬁned as an inhibitor if it decreased
the uptake of model substrate by any of the three transporters by 50%
or more.
Prediction of in Vivo Uptake Clearance. Preparation of Cell
and Tissue Samples for Protein Expression Analysis. HEK293 cells
stably transfected with OATP1B1, OATP1B3, or OATP2B1 were
cultured as described elsewhere
7 until reaching a passage of 19, 17, and
18, respectively. At 95−100% conﬂuence, cells were trypsinized and
centrifuged at 450g for 5 min, followed by one washing step using
phosphate buﬀered saline (PBS). The resulting cell pellets were frozen
at −80 °C until analysis.
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individual donors undergoing surgical liver resection at Uppsala
University Hospital (Uppsala, Sweden), as approved by Uppsala
Regional Ethical Review Board (ethical approval no. 2009/028). All
donors gave their informed consent. The tissue samples were stored at
−80 °C until further analysis.
Extraction of Membrane Proteins and Measurement of
OATP1B1, OATP1B3, and OATP2B1 Protein Expression. For relative
protein quantiﬁcation, HEK293 cells and liver tissue samples were
prepared and analyzed as described previously.
16,45 Brieﬂy, crude
membrane fractions were isolated from the samples and lysed in SDS-
containing buﬀer. Proteins were digested with trypsin according to the
FASP protocol, using 30k ultraﬁltration units. The digests were loaded
on SAX-pipet tip columns at pH 11, and the peptides were eluted with
ab u ﬀer of pH 2. LC-MS/MS analysis of the samples was carried out
on an Orbitrap instrument using 4 h LC gradients. The relative
abundances of the proteins were calculated using the total signal
intensities of the peptides identifying each protein as determined in
the MaxQuant software (Max Planck Institute of Biochemistry,
Martinsried, Germany).
For the targeted protein quantiﬁcation, membrane fractions from
the frozen HEK293 cells and from one representative human liver
tissue sample were extracted and digested with trypsin as previously
described.
36 The targeted OATP proteins were quantiﬁed by peptide-
based LC-MS/MS measurements as a surrogate of proteins levels, with
the addition of stable isotope labeled internal standard peptides that
are speciﬁc for each OATP.
In Vitro to in Vivo Extrapolations Using the Maximal Transport
Activity. A static mathematical model was used to estimate the
contribution of each OATP to the intrinsic uptake CL (CLint,uptake)o f
atorvastatin in vivo. The model was based on in vitro kinetic results of
atorvastatin uptake in OATP overexpressing HEK293 cells. An
intersystem extrapolation factor based on the ratio of the OATP
protein abundances (obtained using targeted proteomics quantiﬁca-
tion) in the cell lines (protein expressionin vitro) to those in human liver
tissue (protein expressionin vivo) was used to calculate the MTA,
assuming that the protein expression is directly proportional to the
maximal velocity (Vmax) and that the amount of membrane protein per
total amount of protein is equal in the two systems (see eq 7).
=× V MTA
protein expression
protein expression
in vivo
in vitro
max(in vitro)
(7)
This is in line with previously published work, where the so-called
relative expression factor, representing the ratio of protein expression
between human hepatocytes and in vitro cell models, measured by
Western blotting, was used as an in vitro to in vivo scaling factor.
5a
The intrinsic uptake CL of each OATP was predicted using eq 8:
=
+
×
K
CL
MTA
[S]
HomPPGL int,uptake
m (8)
where MTA is the estimated maximal velocity in vivo using the scaling
factor explained above, [S] is the atorvastatin concentration
(Cmax,unbound =2n M
46), and HomPPGL is milligrams of homogenate
protein per gram of liver (88 ± 14 mg/g, data based on 12 protein
measurements using the Pierce 660 nm Protein Assay kit with addition
of ionic detergent compatibility reagent (Pierce Biotechnology,
Rockford, IL, USA)). The overall intrinsic uptake CL of atorvastatin
in vivo was derived as the sum of the intrinsic uptake CL of each
individual OATP. This approach is similar to the one described by
Proctor et al. for CYPs but with proteomics data used as an
intersystem extrapolation factor.
47
Our model was subsequently used to predict the impact of the
subset of 13 compounds (for which IC50 values were determined) on
atorvastatin intrinsic uptake CL at an inhibitor concentration of 10 μM
(a concentration where maximal resolution was expected for this
subset of compounds, because 49% of the IC50 values <10 μM and
51% of the IC50 values >10 μM), assuming competitive inhibition and
using the following equation:
48
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where Km is the atorvastatin concentration at half-maximal velocity in
vitro, [I] is the inhibitor concentration (10 μM), and Ki is the
inhibition constant determined using eq 5. As above, the overall
intrinsic uptake CL of atorvastatin in vivo in presence of an inhibitor
was derived as the sum of the intrinsic uptake CL of each individual
OATP.
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